Key result
Oseltamivir and intensive support successfully manage rare Influenza B-induced cardiogenic shock and multiorgan failure.
Why the study?
Influenza-induced cardiogenic shock is rare, with the majority of reported cases resulting from Influenza A rather than Influenza B myocarditis.
Case Report (n=1)
Influenza B can rarely induce myocarditis and cardiogenic shock, which can be successfully managed with antiviral and supportive therapies.
May support oseltamivir and supportive care in rare Influenza B cardiogenic shock; leaves open need for prospective data.
Influenza induced cardiogenic shock is rare and the majority of reported cases are a result of Influenza A myocarditis. We describe a patient with Influenza B who developed myocarditis and cardiogenic shock, with no known pre-existing heart disease. The patient's disease progressed to include rhabdomyolysis, compartment syndrome, renal failure, and pneumonia. He was successfully managed with Oseltamivir, renal replacement therapy, antimicrobials and intubation. This case is notable due to the rarity of influenza B induced cardiogenic shock and reinforces the importance of recognition and treatment.
No takes yet. Share an insight, caveat, or question.
Murnaghan et al. (2022) conducted a case report in Influenza B induced cardiogenic shock (n=1). Oseltamivir, renal replacement therapy, antimicrobials and intubation was evaluated on Clinical recovery. A patient with rare Influenza B induced cardiogenic shock and multiorgan failure was successfully managed with Oseltamivir, renal replacement therapy, antimicrobials, and intubation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: